Article
Oncology
MacLean S. Hall, Jamie K. Teer, Xiaoqing Yu, Holly Branthoover, Sebastian Snedal, Madeline Rodriguez-Valentin, Luz Nagle, Ellen Scott, Ben Schachner, Patrick Innamarato, Amy M. Hall, Jamie Blauvelt, Carolyn J. Rich, Allison D. Richards, Jake Ceccarelli, T. J. Langer, Sean J. Yoder, Matthew S. Beatty, Cheryl A. Cox, Jane L. Messina, Daniel Abate-Daga, James J. Mule, John E. Mullinax, Amod A. Sarnaik, Shari Pilon-Thomas
Summary: This study highlights the importance of neoantigen-specific CD4(+)T cells within tumor-infiltrating lymphocytes (TILs) as a potent source of tumor-specific effectors. The findings suggest that these CD4(+)T cells play a significant role in antitumor immunity and should be included in future adoptive cell therapy (ACT) protocols to improve treatment efficacy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Immunology
Yue Zhao, Alexey Baldin, Orkhan Isayev, Jens Werner, Andrey A. Zamyatnin, Alexandr Bazhin
Summary: Cancer vaccines utilize the host's immune system specificity to eliminate tumor cells, with antigen selection and application playing a critical role in efficacy. Tumor-associated antigens and tumor-specific antigens have different characteristics and applications in vaccine development.
Article
Oncology
Bradley Sinclair White, Sivasish Sindiri, Victoria Hill, Billel Gasmi, Shirley Nah, Jared J. Gartner, Todd D. Prickett, Yong Li, Devikala Gurusamy, Paul Robbins, Steven A. Rosenberg, Vid Leko
Summary: Metastatic cholangiocarcinoma (CC), a type of gastrointestinal cancer, has a poor prognosis and cannot be cured by current therapies. Previous research has shown that adoptive transfer of autologous tumor infiltrating lymphocytes (TILs) that recognize tumor-specific mutations can lead to cancer regression. This study aimed to determine if TILs could recognize FGR2 fusions in patients with CC.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Chaoting Zhang, Yizhe Sun, Shance Li, Luyan Shen, Xia Teng, Yefei Xiao, Nan Wu, Zheming Lu
Summary: The study found that restoring autophagic flux of exhausted TILs through spermidine treatment can enhance the diversity of TCR repertoire, reduce the expression of inhibitory immunoreceptors (PD1, TIM3, or LAG3), improve proliferation and effector functions, leading to superior in vitro and in vivo antitumor activity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Chemistry, Multidisciplinary
Yang Bo, Hua Wang
Summary: Cancer immunotherapies, including therapeutic cancer vaccines, have revolutionized cancer treatment. However, the limited efficacy of cancer vaccines, especially for immunologically cold solid tumors, remains a challenge. In situ cancer vaccines, particularly biomaterials-based vaccines, have emerged as a promising approach to address this challenge by generating endogenous antigens directly from tumors. This review provides an overview of biomaterials-based in situ cancer vaccines, discussing their design criteria and potential applications.
ADVANCED MATERIALS
(2023)
Article
Multidisciplinary Sciences
Reza Naghavian, Wolfgang Faigle, Pietro Oldrati, Jian Wang, Nora C. Toussaint, Yuhan Qiu, Gioele Medici, Marcel Wacker, Lena K. Freudenmann, Pierre-Emmanuel Bonte, Michael Weller, Luca Regli, Sebastian Amigorena, Hans-Georg Rammensee, Juliane S. Walz, Silvio D. Brugger, Malte Mohme, Yingdong Zhao, Mireia Sospedra, Marian C. Neidert, Roland Martin
Summary: Microbial organisms play important roles in physiological processes in the human body and can affect the response to immune checkpoint inhibitors. This study investigates the role of microbial organisms in immune reactivity against glioblastoma. The findings suggest that bacterial pathogens and gut microbiota may be involved in specific immune recognition of tumor antigens, revealing potential for personalized tumor vaccination approaches.
Review
Immunology
Ban Qi Tay, Quentin Wright, Rahul Ladwa, Christopher Perry, Graham Leggatt, Fiona Simpson, James W. Wells, Benedict J. Panizza, Ian H. Frazer, Jazmina L. G. Cruz
Summary: Advances in genetics, molecular biology, biochemistry, and immunology have led to promising developments in cancer vaccine research, with novel delivery methods and combination therapies offering new hope for the future of cancer vaccines.
Article
Oncology
Anders Handrup Kverneland, Christopher Aled Chamberlain, Troels Holz Borch, Morten Nielsen, Sofie Kirial Mork, Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Lise Pyndt Jorgensen, Lene Buhl Riis, Christina Westmose Yde, Ozcan Met, Marco Donia, Inge Marie Svane
Summary: This study demonstrated high success rates of TIL expansion and tumor regressions in multiple solid cancer types when combining TIL ACT with CPIs. In vitro tumor reactivity was positively associated with treatment outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Immunology
Fatemeh Zahedipour, Khadijeh Jamialahmadi, Parvin Zamani, Mahmoud Reza Jaafari
Summary: Peptide vaccines have shown potential in cancer immunotherapy by targeting tumor antigens and activating the immune system, but their efficacy is still a major challenge. This review discusses the current status and strategies to improve the efficacy of peptide vaccines, including the use of novel adjuvants, neoantigens, nano-delivery systems, and combination therapies. Personalized cancer vaccines, multivalent peptides, conjugated peptides, fusion proteins, and self-assembled peptides are also highlighted as ways to enhance the immunogenicity of peptide vaccines. Combining peptide vaccines with other immunotherapeutic approaches and developing personalized vaccines can significantly improve their efficacy and clinical outcomes for cancer patients.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
David Reparaz, Belen Aparicio, Diana Llopiz, Sandra Hervas-Stubbs, Pablo Sarobe
Summary: Immune checkpoint inhibitors (ICI) show promising results but still have limitations in hepatocellular carcinoma (HCC) immunotherapy. Understanding immune elements in the tumor microenvironment may help personalize therapies and improve non-responder patients. Vaccination and boosting responses against tumor-specific antigens may complement ICI treatment in certain HCC cases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Priyanka G. Bhosale, Robert A. Kennedy, Fiona M. Watt
Summary: Oral squamous cell carcinomas (OSCCs) are genetically diverse and have different microenvironments. Despite the presence of lymphocytes, the activation of CASP8 and CASP3 is low in tumors, while apoptosis is high in lymphocytes. Higher FasL expression in CASP8 mutated tumors may predict disease progression.
JOURNAL OF PATHOLOGY
(2023)
Article
Oncology
Ithar Gataa, Laura Mezquita, Caroline Rossoni, Edouard Auclin, Myriam Kossai, Frank Aboubakar, Sylvestre Le Moulec, Julie Masse, Morgane Masson, Nina Radosevic-Robin, Pierre Alemany, Mathieu Rouanne, Virginia Bluthgen, Lizza Hendriks, Caroline Caramella, Anas Gazzah, David Planchard, Jean-Pierre Pignon, Benjamin Besse, Julien Adam
Summary: High-TIL was associated with favorable outcomes in a real-world immunotherapy cohort of patients with NSCLC, but not with chemotherapy, suggesting that TILs may be useful in selecting patients for immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Samantha M. Fix, Marie-Andree Forget, Donastas Sakellariou-Thompson, Yunfei Wang, Tamara M. Griffiths, Minjung Lee, Cara L. Haymaker, Ana Lucia Dominguez, Rafet Basar, Christopher Reyes, Sanjay Kumar, Larissa A. Meyer, Patrick Hwu, Chantale Bernatchez, Amir A. Jazaeri
Summary: In this study, we optimized CRISPR/Cas9-mediated knockout of TGF-beta receptor 2 (TGFBR2) in patient-derived ovarian cancer TIL. TGFBR2 knockout TIL showed resistance to immunosuppression and improved cytotoxicity. This lays the groundwork for clinical translation of CRISPR-modified TIL for the treatment of ovarian cancer and other solid cancers.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Sara Valpione, Luca G. Campana, John Weightman, Zena Salih, Elena Galvani, Piyushkumar A. Mundra, Francesco De Rosa, Avinash Gupta, Patricio Serra-Bellver, Paul Lorigan, Theodora Germetaki, Marek Dynowski, Stephen Kitcatt, Sudhakar Sahoo, Dave Lee, Nathalie Dhomen, Graham Lord, Richard Marais
Summary: This study explored the role of different immune cell subsets in anti-tumor responses to checkpoint inhibitors. It found that B cells play a crucial role in clinical response and may contribute to anti-tumor immunity through antigen presentation. Additionally, the abundance of tumor-infiltrating B cell clonotypes at baseline can identify distinct risk groups and serve as a promising prognostic biomarker for clinical risk stratification.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Oncology
Marcus Schmidt, Anne-Sophie Heimes
Summary: The immune system plays a crucial role in breast cancer, particularly in triple negative breast cancer. Personalized mRNA vaccines targeting tumor-specific neoantigens and immune checkpoint inhibitors are emerging as promising treatment strategies.
Review
Oncology
Jugal Kishore Das, Xiaofang Xiong, Xingcong Ren, Jin-Ming Yang, Jianxun Song
JOURNAL OF ONCOLOGY
(2019)
Article
Multidisciplinary Sciences
Jugal Kishore Das, Yijie Ren, Anil Kumar, Hao-Yun Peng, Liqing Wang, Xiaofang Xiong, Robert C. Alaniz, Paul de Figueiredo, Xingcong Ren, Xiaoqi Liu, Alexey G. Ryazonov, Jin-Ming Yang, Jianxun Song
Summary: eEF-2K plays a critical role in regulating the fate and function of CD8(+) T cells. Loss of eEF-2K leads to increased proliferation but decreased survival of CD8(+) T cells, along with premature senescence and exhaustion. eEF-2K deficiency also affects the metabolic activity of CD8(+) T cells and the effectiveness of CAR-T therapy against cancer.
Article
Virology
Liqing Wang, Anil Kumar, Jugal Kishore Das, Yijie Ren, Hao-Yun Peng, Darby Jane Ballard, Xiaofang Xiong, Jacob Rance Davis, Xingcong Ren, Jin-Ming Yang, Jianxun Song
Summary: The study found that NAC1 regulates the memory formation of CD8(+) T cells by modulating IRF4. NAC1(-/-) mice display enhanced memory formation of viral antigen-specific CD8(+) T cells.
Article
Multidisciplinary Sciences
Jin-Ming Yang, Yijie Ren, Anil Kumar, Xiaofang Xiong, Jugal Kishore Das, Hao-Yun Peng, Liqing Wang, Xingcong Ren, Yi Zhang, Cheng Ji, Yan Cheng, Li Zhang, Robert C. Alaniz, Paul de Figueiredo, Deyu Fang, Hongwei Zhou, Xiaoqi Liu, Jianlong Wang, Jianxun Song
Summary: This study shows that NAC1 plays a role in regulating the expression of FoxP3 in regulatory T cells, thereby affecting immune tolerance. NAC1-deficient mice display increased tolerance to autoimmunity and higher levels of immune-suppressive CD4(+) T-regs cells which exhibit enhanced metabolic profile and activity. These findings suggest that NAC1 destabilizes T-regs and suppresses tolerance induction, indicating its potential as a target for tolerogenic strategies in treating autoimmune disorders.